Core Insights - Jiangzhong Pharmaceutical reported an increase in shareholder accounts to 39,013 as of June 30, 2025, reflecting a growth of 446 accounts or 1.16% compared to March 31, 2025 [1][2] - The average market value per shareholder for Jiangzhong Pharmaceutical is 355,300 yuan, which is above the industry average of 236,000 yuan [1][2] - The stock price of Jiangzhong Pharmaceutical saw a slight increase of 0.09% from March 31, 2025, to June 30, 2025, during which the number of shareholders increased [1][2] Shareholder Statistics - As of June 30, 2025, Jiangzhong Pharmaceutical had 39,013 shareholders, an increase of 446 accounts or 1.16% from the previous quarter [2] - The average number of shares held per shareholder remained stable at 16,300 shares [2] - The average market value per shareholder decreased slightly from 367,000 yuan on March 31, 2025, to 355,300 yuan on June 30, 2025 [2] Stock Performance - From March 31, 2025, to June 30, 2025, Jiangzhong Pharmaceutical's stock price increased by 0.09% [1][2] - During the same period, the net inflow of funds from major investors was 33.37 million yuan, while retail investors contributed a net inflow of 21.22 million yuan [2] - In contrast, speculative funds experienced a net outflow of 54.59 million yuan [2]

Investment Rating - The report maintains a rating of "Add" for Jiangzhong Pharmaceutical [4] Core Views - The company demonstrates strong resilience in performance, with its health business stabilizing and recovering after restructuring [2] - Jiangzhong Pharmaceutical continues its tradition of high dividends, highlighting its long-term investment value [3] - The company is focused on expanding its product categories and enhancing channel strength, which is expected to drive revenue growth [3] Financial Summary - For 2023A, the company reported revenue of 4,553 million yuan, with a year-on-year growth rate of 17.2%. The projected revenue for 2025E is 4,287 million yuan, reflecting a decline of 3.4% [1] - The net profit attributable to the parent company for 2023A is 719 million yuan, with a year-on-year growth rate of 20.1%. The projected net profit for 2025E is 868 million yuan, indicating a growth of 10.2% [1] - The company plans to distribute a cash dividend of 0.50 yuan per share, which accounts for 60.78% of the net profit for the first half of 2025 [3] Strategic Positioning - Jiangzhong Pharmaceutical's strategy includes strengthening its OTC business, developing health consumer products, and expanding its prescription drug offerings [2] - The company aims to enhance its product matrix through brand integration and digital marketing, while also exploring high-quality resource integration and business development partnerships [2] - The company has a talent incentive mechanism in place, with over 50% of its research personnel benefiting from equity incentives, which is expected to stimulate innovation [2]

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company demonstrated resilience in operations despite industry pressures, with a focus on health consumer products and prescription drugs showing growth [2]. - The company is positioned as a leading player in the OTC market for gastrointestinal products in China, with expectations for steady growth through both organic and external means [1]. - The company has implemented cost optimization strategies that have led to improved profitability and stable cash flow [3]. Summary by Sections Financial Performance - For the first half of 2025, the company reported revenues of 2.14 billion RMB, a decrease of 6% year-on-year, while net profit attributable to shareholders was 520 million RMB, an increase of 6% year-on-year [1]. - The second quarter of 2025 saw revenues of 960 million RMB, a decline of 4% year-on-year, but net profit attributable to shareholders increased by 6% to 240 million RMB [1]. - The gross margin for the first half of 2025 was 66.6%, down 2.4 percentage points year-on-year, primarily due to a decrease in the proportion of high-margin OTC business [3]. Business Segments - The OTC segment faced challenges with revenues of 1.55 billion RMB, down 10% year-on-year, while health consumer products grew by 17% to 230 million RMB, and prescription drugs increased by 7% to 360 million RMB [2]. - The company has strengthened its online marketing channels and brand building, which contributed to the growth in health consumer products [2]. Dividend Policy - The company announced a cash dividend of 0.5 RMB per share for the first half of 2025, representing 60.78% of the net profit attributable to shareholders [1][4]. - The company plans to maintain a high dividend payout ratio during the 14th Five-Year Plan period, emphasizing its commitment to shareholder returns [4]. Future Outlook - The company forecasts net profits attributable to shareholders of 897 million RMB, 1.015 billion RMB, and 1.145 billion RMB for 2025, 2026, and 2027, respectively, reflecting growth rates of 14%, 13%, and 13% year-on-year [5]. - The target price for the company's stock is set at 29.96 RMB, based on a 21x PE ratio for 2025 [5].

Investment Rating - The investment rating for Jiangzhong Pharmaceutical is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 2.141 billion yuan in H1 2025, a year-on-year decrease of 5.79%, while the net profit attributable to shareholders was 522 million yuan, an increase of 5.80% [4] - The gross margin for H1 2025 was 66.60%, down by 2.44 percentage points, and the net margin was 26.13%, up by 1.99 percentage points [4] - The company is optimistic about its long-term development potential in the gastrointestinal and related medication sectors, maintaining profit forecasts for 2025-2027 with net profits expected to be 891 million, 1.008 billion, and 1.131 billion yuan respectively [4] Financial Performance Summary - In H1 2025, the non-prescription drug business revenue was 1.550 billion yuan, down 10.14%, while the prescription drug business revenue was 360 million yuan, up 7.44% [5] - The company is focusing on digital transformation to enhance efficiency and is actively pursuing mergers and acquisitions to expand its product matrix [6] - The financial summary indicates that the company expects revenue growth of 8.7% in 2025, with a projected net profit growth of 13.0% [8]

Summary of Key Points Core Viewpoint - Jiangzhong Pharmaceutical announced a semi-annual distribution plan for 2025, proposing a cash dividend of 5 yuan per 10 shares, totaling 317 million yuan, which represents 60.78% of its net profit for the period. The dividend yield is calculated at 2.22% based on the average trading price for the period [2]. Distribution History - The company has a history of dividend distributions since its listing, with the latest proposal marking the 30th distribution. The cash distribution amounts and dividend yields have varied over the years, with notable distributions including: - 2024.12.31: 10派7元, 444 million yuan, 3.04% yield - 2023.12.31: 10派7元, 441 million yuan, 3.48% yield - 2022.12.31: 10派6.5元, 409 million yuan, 4.51% yield [1][2]. Financial Performance - For the first half of 2025, Jiangzhong Pharmaceutical reported operating revenue of 2.141 billion yuan, a year-on-year decrease of 5.79%. However, net profit increased by 5.80% to 522 million yuan, with basic earnings per share at 0.82 yuan [3]. Market Activity - The stock experienced a net outflow of 2.931 million yuan in principal funds on the day of the announcement, with a total net outflow of 27.178 million yuan over the past five days [4]. - The latest margin financing balance for the stock is 244 million yuan, reflecting a decrease of 4.394 million yuan over the past five days, a decline of 1.77% [5]. Industry Comparison - In the pharmaceutical and biotechnology sector, Jiangzhong Pharmaceutical's cash distribution of 317.5 million yuan ranks it among the top companies, with WuXi AppTec leading at 1 billion yuan, followed by China Resources Sanjiu and Baiyunshan at 751 million yuan and 650 million yuan, respectively [5].

Core Viewpoint - Jiangzhong Pharmaceutical announced the reappointment of KPMG Huazhen LLP as the auditing firm for the fiscal year 2025 [2] Group 1 - The company intends to continue its relationship with KPMG Huazhen LLP for auditing services [2]

（文章来源：证券日报） 证券日报网讯 8月21日晚间，江中药业发布公告称，2025年半年度公司实现营业收入2，141，118， 142.51元，同比下降5.79%；归属于上市公司股东的净利润为522，337，503.28元，同比增长5.80%。 ...

（文章来源：证券日报） 证券日报网讯 8月21日晚间，江中药业发布公告称，公司第十届监事会第七次会议审议通过了《关于续 聘2025年度审计机构的议案》等多项议案。 ...

（编辑 任世碧） 证券日报网讯 8月21日晚间，江中药业发布关于2025年半年度利润分配方案的公告称，公司拟以实施权 益分派股权登记日公司总股本为基数，向全体股东每10股派发现金红利5元（含税）。公司目前尚难以 预计本次实施权益分派股权登记日时有权参与本次利润分配的总股数（"实际有权参与股数"），因此暂 无法确定本次利润分配现金分红总额。若以2025年半年度末公司总股本634，996，022股为基数计算， 每10股派发5元（含税），共计派发31，749.80万元。本次现金分红金额占2025年半年度合并报表中归 属于母公司所有者的净利润的60.78%。 ...

Growth - Teva Pharmaceutical reported a net profit of 38.01 million yuan in the first half of the year, a year-on-year increase of 1313.23% [1] - Qianfang Technology achieved a net profit of 170 million yuan, up 1287.12% year-on-year [1] - Tianyu Digital Science and Technology recorded a net profit of 23.62 million yuan, reflecting a 453.67% increase [1] - Suzhou Gude reported a net profit of 43.70 million yuan, up 310.28% year-on-year [1] - Sainuo Medical achieved a net profit of 13.84 million yuan, an increase of 296.54% [1] - Runfeng Co., Ltd. reported a net profit of 556 million yuan, up 205.62% year-on-year [1] - Guodian Nanzi achieved a net profit of 159 million yuan, reflecting a 197.03% increase [1] - Ruijie Networks reported a net profit of 452 million yuan, up 194% year-on-year [1] - Zhongjing Technology achieved a net profit of 25.74 million yuan, an increase of 144.05% [1] - China National Materials Technology reported a net profit of 999 million yuan, up 114.92% year-on-year [1] - Lante Optics achieved a net profit of 103 million yuan, reflecting a 110.27% increase [1] - Yidao Information reported a net profit of 11.41 million yuan, up 96.02% year-on-year [1] - Qianzhao Optoelectronics achieved a net profit of 69.23 million yuan, an increase of 88.04% [1] - Ruile New Materials reported a net profit of 166 million yuan, up 74.22% year-on-year [1] - Lvtian Machinery achieved a net profit of 140 million yuan, reflecting a 64.36% increase [1] - Mega Chip Color reported a net profit of 110 million yuan, up 48.83% year-on-year [1] - Jiaojian Co., Ltd. achieved a net profit of 113 million yuan, an increase of 48.66% [1] - Huhua Electronics reported a net profit of 1.683 billion yuan, up 47.50% year-on-year [1] - Sany Heavy Industry achieved a net profit of 5.216 billion yuan, reflecting a 46% increase [1] - Goodix Technology reported a net profit of 431 million yuan, up 35.74% year-on-year [1] - Allwinner Technology achieved a net profit of 161 million yuan, an increase of 35.36% [1] - Bichu Electronics reported a net profit of 640 million yuan, up 30.32% year-on-year [1] - Ganneng Co., Ltd. achieved a net profit of 438 million yuan, reflecting a 29.39% increase [1] - Weigao Medical reported a net profit of 492 million yuan, up 28.07% year-on-year [1] - GoerTek achieved a net profit of 1.417 billion yuan, reflecting a 15.65% increase [1] - Huason Pharmaceutical reported a net profit of 53.95 million yuan, up 14.27% year-on-year [1] - Gaoxin Development achieved a net profit of 66.92 million yuan, an increase of 14.06% [1] - Shanghai Jahwa reported a net profit of 266 million yuan, up 11.66% year-on-year [1] Stable Growth - Hangcha Group reported a net profit of 1.121 billion yuan, reflecting an increase of 11.38% year-on-year [2] - Dong'e Ejiao achieved a net profit of 818 million yuan, up 10.74% [2] - Beikong Technology reported a net profit of 54.31 million yuan, an increase of 10.59% [2] - Hongxin Electronics achieved a net profit of 53.99 million yuan, up 9.85% year-on-year [2] - Huace Testing reported a net profit of 467 million yuan, reflecting a 7.03% increase [2] - Samsung Medical achieved a net profit of 1.230 billion yuan, up 6.93% year-on-year [2] - Jiangzhong Pharmaceutical reported a net profit of 522 million yuan, reflecting a 5.80% increase [2] - Hualing Cable achieved a net profit of 63.64 million yuan, up 4.74% year-on-year [2] - Kuaijishan reported a net profit of 93.88 million yuan, reflecting a 3.41% increase [2] - Laishen Tongling achieved a net profit of 60.61 million yuan, turning from loss to profit [2] - Yunnan Geology reported a net profit of 22.15 million yuan, turning from loss to profit [2] - Shandong Steel achieved a net profit of 1.253 million yuan, turning from loss to profit [2] Decline and Loss - Zhongtian Rocket reported a net profit of 394,460 yuan, a year-on-year decrease of 80.74% [2] - Liuhua Co., Ltd. achieved a net profit of 344,280 yuan, down 78.01% year-on-year [2] - Qiaqia Food reported a net profit of 886.42 million yuan, a decrease of 73.68% [2] - Hangjin Technology achieved a net profit of 1.372 million yuan, down 58.38% year-on-year [2] - Taiping Bird reported a net profit of 7.771 million yuan, a decrease of 54.61% [2] - Canadian Solar reported a net profit of 731 million yuan, down 41.01% year-on-year [2] - Sinopec achieved a net profit of 21.483 billion yuan, a decrease of 39.8% [2] - Fulejia reported a net profit of 230 million yuan, down 32.54% year-on-year [2] - Palin Bio reported a net profit of 236 million yuan, down 27.89% [2] - Yiwei Lithium Energy achieved a net profit of 1.605 billion yuan, down 24.9% year-on-year [2] - Jinguang Electric reported a net profit of 42.34 million yuan, down 17.16% [2] - Hexing Co., Ltd. achieved a net profit of 107 million yuan, down 16.98% year-on-year [2] - Electric Investment Production and Financing reported a net profit of 459 million yuan, down 13.41% [2] - Tiantan Biological achieved a net profit of 633 million yuan, down 12.88% year-on-year [2] - Huali Group reported a net profit of 1.671 billion yuan, down 11.06% [2] - Zhongyou Engineering achieved a net profit of 470 million yuan, down 10.87% year-on-year [2] Further Losses - Chongda Technology reported a net profit of 222 million yuan, down 6.19% year-on-year [3] - Xinhua Department Store achieved a net profit of 86.01 million yuan, down 2.52% [3] - Zhuosheng Micro reported a net loss of 147 million yuan, turning from profit to loss [3] - Penghui Energy reported a net loss of 88.23 million yuan, turning from profit to loss [3] - Yipin Hong reported a net loss of 73.54 million yuan, turning from profit to loss [3] - Zhongbing Hongjian reported a net loss of 40.71 million yuan, turning from profit to loss [3] - Sanwei Xinan reported a net loss of 29.39 million yuan, turning from profit to loss [3] - Anyuan Coal reported a net loss of 290 million yuan [3] - Keda Xunfei reported a net loss of 239 million yuan [3] - Jishi Media reported a net loss of 23.2 million yuan [3] - Nanjing Chemical Fiber reported a net loss of 88.93 million yuan [3] - Guangsheng Tang reported a net loss of 66.69 million yuan [3] - Chutian Long reported a net loss of 39.77 million yuan [3]